Mineralys Therapeutics, Inc. Common Stock (MLYS) is a publicly traded Healthcare sector company. As of July 11, 2026, MLYS trades at $28.10 with a market cap of $2.55B and a P/E ratio of -12.32. MLYS moved -2.07% today. Year to date, MLYS is -21.80%; over the trailing twelve months it is +93.85%. Its 52-week range spans $8.24 to $47.65. Analyst consensus is strong buy with an average price target of $50.40. Rallies surfaces MLYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
7 analysts cover MLYS: 0 strong buy, 7 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $50.40.
| Metric | Value |
|---|---|
| Price | $28.10 |
| Market Cap | $2.55B |
| P/E Ratio | -12.32 |
| EPS | $-2.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $47.65 |
| 52-Week Low | $8.24 |
| Volume | 573.58K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-154.65M |
| Gross Margin | 0.00% |
7 analysts cover MLYS: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.40.